Psychedelics and Pot Investors Look Beyond the Hype
Cannabis and psychedelics stocks continue to suffer. Here's a look at how the hype has failed to materialize.
Photographer: Dimas Ardian/BloombergThis will be the last issue of the Dose, as I open a new chapter, digging into bigger stories about the science, regulation and money flows that will make or break the many small companies in cannabis and psychedelics. Watch for future stories on Bloomberg's main platform, where you can subscribe to alerts on my stories, in our Prognosis health newsletter, or connect with me on LinkedIn or X.
Much like cryptocurrency, the cannabis and psychedelics industries have failed to live up to the hype.